Daily Respiratory Research Analysis
Analyzed 132 papers and selected 3 impactful papers.
Summary
Analyzed 132 papers and selected 3 impactful articles.
Selected Articles
1. A sustainable house design to improve child health in rural Africa: a cluster-randomized controlled trial.
In a three-year cluster-randomized trial comparing 110 novel “Star Homes” to 513 traditional houses, children living in Star Homes experienced 44% less malaria, 30% less diarrhea, and 18% fewer acute respiratory infections. The intervention bundled insect-proofing, improved ventilation (cooler, smoke-free), and reliable water/sanitation, with additional gains in linear growth among children under five.
Impact: This pragmatic built-environment intervention demonstrates population-level prevention of respiratory infections, offering a scalable, non-pharmaceutical strategy. The robust RCT design across multiple outcomes is likely to influence public health and housing policy.
Clinical Implications: Public health and policy stakeholders can reduce pediatric ARI burden by integrating insect-proof, smoke-free, well-ventilated housing with water and sanitation improvements in endemic settings. Health systems should consider housing upgrades as part of respiratory disease prevention strategies.
Key Findings
- Children in Star Homes had 18% fewer acute respiratory infections compared with traditional homes (IRR 0.82, 95% CI 0.73–0.93).
- Malaria and diarrhea were reduced by 44% (IRR 0.56, 95% CI 0.43–0.72) and 30% (IRR 0.70, 95% CI 0.53–0.91), respectively.
- Children under five living in Star Homes showed improved height-for-age, suggesting broader health benefits.
Methodological Strengths
- Cluster-randomized controlled design with multi-year follow-up and multiple clinically relevant outcomes
- Pragmatic, real-world implementation integrating housing, water, and sanitation features
Limitations
- Open-label design may introduce behavioral changes unrelated to specific components
- Bundle intervention precludes attribution to individual features; generalizability beyond study region requires validation
Future Directions: Disaggregate which housing components most reduce ARIs; cost-effectiveness analyses; scale-up evaluations across diverse climates and health systems.
Malaria, diarrhea and acute respiratory infections (ARIs) are the major causes of mortality in young children in sub-Saharan Africa. Here we provide support for the hypothesis that children can be protected from these diseases by improvements in house design. We designed a novel double-story house, called a Star Home, to provide an insect-proof, cleaner, cooler and smoke-free environment, with a reliable supply of water and sanitation. We conducted a cluster-randomized controlled trial where households with chil
2. Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.
Across two open-label randomized platform trials in vaccinated higher-risk outpatients, nirmatrelvir-ritonavir did not reduce 28-day hospitalization or death versus usual care, although a virologic substudy showed reduced viral load. Event rates were low, with Bayesian probabilities of superiority not meeting prespecified thresholds.
Impact: This large, pragmatic RCT directly informs outpatient COVID-19 antiviral use in vaccinated populations, challenging current assumptions of benefit in lower-event-rate settings.
Clinical Implications: For vaccinated higher-risk outpatients, routine prescribing of nirmatrelvir-ritonavir solely to prevent hospitalization/death may be unwarranted; prioritization should consider absolute risk, potential drug–drug interactions, and patient values.
Key Findings
- In PANORAMIC, hospitalization/death was 0.8% vs 0.7% (aOR 1.18; 95% Bayesian CrI 0.55–2.62; superiority probability 0.334).
- In CanTreatCOVID, hospitalization/death was 0.6% vs 1.2% (aOR 0.48; 95% Bayesian CrI 0.08–2.23; superiority probability 0.830).
- A substudy (n=634) showed reduced viral load at end of treatment with nirmatrelvir-ritonavir.
Methodological Strengths
- Large randomized platform design across two countries; prespecified Bayesian analyses
- Inclusive of vaccinated and previously infected populations with virologic substudy
Limitations
- Open-label design may influence care-seeking or ancillary treatments
- Low event rates limit power to detect modest benefits; variant-era heterogeneity across trials
Future Directions: Identify subgroups with higher absolute risk who may benefit; integrate real-world pharmacovigilance and resistance monitoring; evaluate combination antivirals.
BACKGROUND: Nirmatrelvir-ritonavir has been shown to reduce progression to severe illness from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in unvaccinated high-risk outpatients. The effectiveness of nirmatrelvir-ritonavir in persons who have been vaccinated, infected naturally, or both is unclear. METHODS: In two open-label platform trials (PANORAMIC in the United Kingdom and CanTreatCOVID in Canada), we enrolled higher-risk adults (≥50 years of age or ≥18 years of age with coexisting conditions) in the community who tested positive for SARS-CoV-2 and had been unwell for 5 days or less. The participants were randomly assigned to receive usual care plus nirmatrelvir (300 mg)-ritonavir (100 mg) twice a day for 5 days or to receive usual care alone. The primary outcome was hospitalization or death from any cause within 28 days after randomization. RESULTS: From December 8, 2021, to September 30, 2024, a total of 3516 participants in the PANORAMIC trial and 716 participants in the CanTreatCOVID trial underwent randomization. In the PANORAMIC trial, 14 of 1698 participants (0.8%) in the nirmatrelvir-ritonavir group and 11 of 1673 participants (0.7%) in the usual-care group were hospitalized or died (adjusted odds ratio, 1.18; 95% Bayesian credible interval, 0.55 to 2.62; probability of superiority, 0.334). In the CanTreatCOVID trial, 2 of 343 participants (0.6%) in the nirmatrelvir-ritonavir group and 4 of 324 participants (1.2%) in the usual-care group were hospitalized or died (adjusted odds ratio, 0.48; 95% Bayesian credible interval, 0.08 to 2.23; probability of superiority, 0.830). In a substudy involving 634 participants, viral load was reduced by the end of treatment with nirmatrelvir-ritonavir. Serious adverse events with nirmatrelvir-ritonavir were reported in 9 participants in the PANORAMIC trial and in 4 participants in the CanTreatCOVID trial. CONCLUSIONS: In two open-label trials, nirmatrelvir-ritonavir did not reduce the incidence of hospitalization or death among vaccinated higher-risk participants with SARS-CoV-2 infection. (Funded by the National Institute for Health and Care Research, and others; PANORAMIC ISRCTN number, 2021-005748-31; CanTreatCOVID ClinicalTrials.gov number, NCT05614349.).
3. Upregulation of CXCL10/CXCR3 Axis Induced by Pulmonary Hemodynamic Stress Promotes Vascular Remodeling in Chronic Thromboembolic Pulmonary Hypertension.
Human CTEPH specimens and a left pulmonary artery ligation rat model reveal that hemodynamic stress upregulates the CXCL10/CXCR3 axis in MRC1+ macrophages and PASMCs, driving proinflammatory macrophage phenotypes and PASMC hyperproliferation. Pharmacologic CXCR3 inhibition (AMG487) and cell type–specific CXCR3 knockdown attenuated pulmonary hypertension and vascular remodeling in preventive and therapeutic paradigms.
Impact: It mechanistically links hemodynamic stress to inflammatory vascular remodeling in CTEPH and provides multi-level target validation for CXCR3, opening a translational path to adjunctive therapies.
Clinical Implications: The CXCL10/CXCR3 axis may serve as a biomarker and therapeutic target to mitigate microvasculopathy in CTEPH, complementing surgical endarterectomy or balloon angioplasty.
Key Findings
- CXCL10 localized to MRC1+ macrophages and CXCR3 was enriched in vascular walls and distal nonoccluded arteries in CTEPH specimens.
- In the LPA ligation model, CXCL10/CXCR3 upregulation, perivascular MRC1+ macrophage accumulation, and PASMC CXCR3 expression promoted PASMC proliferation.
- CXCR3 inhibition with AMG487 and cell-specific CXCR3 knockdown reduced pulmonary hypertension, vascular remodeling, and macrophage accumulation in preventive and therapeutic settings.
Methodological Strengths
- Integration of human surgical specimens with in vivo rat model and in vitro assays
- Convergent pharmacologic (AMG487) and genetic (cell type–specific knockdown) validation
Limitations
- Preclinical nature limits direct clinical generalizability; sample sizes in human tissue analyses not detailed
- CXCR3 inhibitor safety/PK in CTEPH not addressed
Future Directions: Validate circulating/lesional CXCL10/CXCR3 as biomarkers; early-phase trials of CXCR3 modulation in CTEPH; dissect cell-specific contributions and upstream hemodynamic triggers.
BACKGROUND: Perivascular inflammation induced by abnormal hemodynamic stress is increasingly recognized as a key driver of secondary microvasculopathy in chronic thromboembolic pulmonary hypertension. Although circulating CXCL10 (C-X-C motif chemokine ligand 10) is elevated in chronic thromboembolic pulmonary hypertension and correlates with pulmonary hemodynamics, its mechanistic contribution to vascular remodeling remains unclear. METHODS: Experiments were performed using pulmonary endarterectomy specimens from patients with chronic thromboembolic pulmonary hypertension and a left pulmonary artery ligation rat model. RESULTS: In pulmonary endarterectomy specimens, CXCL10 was predominantly localized to CD68+ mannose receptor C-type 1+ macrophages, whereas CXCR3 (C-X-C motif chemokine receptor 3) was broadly expressed in the vascular wall and enriched in distal nonoccluded pulmonary arteries with increased mannose receptor C-type 1+ macrophage accumulation. In left pulmonary artery ligation rats, pulmonary hypertension and vascular remodeling were accompanied by perivascular accumulation of CXCL10+CXCR3+ mannose receptor C-type 1+ macrophages, increased plasma CXCL10, and upregulation of CXCL10 and CXCR3 in the right lung. CXCR3 expression was also increased in pulmonary arterial smooth muscle cells, and CXCL10 directly promoted proliferation of left pulmonary artery ligation-derived PASMCs in a CXCR3-dependent manner. In parallel, CXCL10 drove macrophages toward a proinflammatory, pro-proliferative secretory phenotype, and conditioned medium from macrophages enhanced PASMC proliferation. Pharmacological CXCR3 inhibition with AMG487 attenuated pulmonary hypertension, vascular remodeling, PASMC proliferation, and perivascular macrophage accumulation in both preventive and therapeutic settings. Similarly, cell type-specific CXCR3 knockdown in smooth muscle cells or macrophages ameliorated left pulmonary artery ligation-induced pulmonary hypertension, vascular remodeling, and associated perivascular inflammation. CONCLUSIONS: The CXCL10/CXCR3 axis links hemodynamic stress to pulmonary vascular remodeling in chronic thromboembolic pulmonary hypertension by coordinating PASMC hyperproliferation and macrophage-driven inflammation, and may represent a therapeutic target.